Baird Financial Group’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-3,935
Closed -$231K 1539
2019
Q2
$231K Hold
3,935
﹤0.01% 1427
2019
Q1
$239K Hold
3,935
﹤0.01% 1204
2018
Q4
$216K Sell
3,935
-270
-6% -$16.4K ﹤0.01% 1197
2018
Q3
$269K Sell
4,205
-935
-18% -$58.3K ﹤0.01% 1205
2018
Q2
$303K Sell
5,140
-255
-5% -$14.8K ﹤0.01% 1138
2018
Q1
$307K Sell
5,395
-250
-4% -$14.9K ﹤0.01% 1120
2017
Q4
$335K Sell
5,645
-185
-3% -$10.6K ﹤0.01% 1110
2017
Q3
$337K Sell
5,830
-1,895
-25% -$108K ﹤0.01% 1080
2017
Q2
$456K Sell
7,725
-290
-4% -$16.4K ﹤0.01% 986
2017
Q1
$442K Sell
8,015
-3,600
-31% -$195K ﹤0.01% 981
2016
Q4
$610K Buy
11,615
+40
+0.3% +$2.14K 0.01% 876
2016
Q3
$665K Hold
11,575
0.01% 860
2016
Q2
$704K Sell
11,575
-760
-6% -$44.3K 0.01% 841
2016
Q1
$709K Buy
12,335
+180
+1% +$10.6K 0.01% 823
2015
Q4
$794K Sell
12,155
-6,200
-34% -$400K 0.01% 768
2015
Q3
$1.16M Hold
18,355
0.01% 663
2015
Q2
$1.3M Buy
+18,355
New +$1.32M 0.01% 670

Other funds holding PPH

Baird Financial Group's PPH Position: Q3 2019 in Review

Baird Financial Group sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2019, closing a stake of 3,935 shares — an estimated $231K sold.

Baird Financial Group first reported a position in PPH in Q2 2015 and held it in 17 quarters. The position peaked at $1.3M in Q2 2015. 43 funds tracked by Wall St. Rank hold PPH as of Q3 2019.

  • Baird Financial Group reported no remaining VanEck Pharmaceutical ETF position as of Q3 2019 after selling out during the quarter.
  • Baird Financial Group sold 3,935 VanEck Pharmaceutical ETF shares in Q3 2019, an estimated $231K.
  • Baird Financial Group first reported a position in VanEck Pharmaceutical ETF in Q2 2015 and held it in 17 quarters.
  • Baird Financial Group's VanEck Pharmaceutical ETF position peaked at $1.3M in Q2 2015.
  • 43 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2019.

Based on Baird Financial Group's 13F filing for Q3 2019, filed 14 Nov 2019.